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Oral vitamins C and E as additional treatment in
patients with acute anterior uveitis: a randomised
double masked study in 145 patients
Jeroen van Rooij, Sicco G W S thoe Schwartzenberg, Paul G H Mulder, Seerp G Baarsma
Abstract
Aim—To investigate the eVect of addi-
tional oral vitamins C and E on acute
anterior uveitis.
Methods—A placebo controlled double
masked study on the eVect of vitamin C
500 mg in combination with vitamin E 100
mg twice daily in 145 patients with acute
anterior uveitis. As a primary end point
variable, laser cell/flare measurements
were performed. Best corrected and
stenopeic visual acuity (VA) testing and
clinical variable scores were measured.
Results—Laser flare measurements (ph/s)
before treatment were 207.1 (SD 258) in
the vitamin group and 143.6 (156) in the
placebo group. After 3 days corresponding
values were 80.2 (129) and 54.7 (82), after 7
days 89.2 (187) (12.5) and 85.8 (208), after
14 days 47.1 (109.5) and 40.5 (116) after 28
days 23.1 (53.6) and 23.1 (48), and after 56
days 15.6 (26) and 15.3 (17). There was no
significant diVerence in time trend be-
tween the two treatment groups
(RMANOVA; p = 0.53). Baseline VA (log-
MAR) was 0.106 (0.241) in the vitamin
group and 0.128 (0.456) in the placebo
group. VA after 3 days was 0.236 (0.293)
and 0.344 ( 0.489), after 7 days 0.204 (0.292)
and 0.292 (0.479), after 14 days 0.162
(0.274) and 0.193 (0.454), after 28 days
0.096 (0.232) and 0.158 (0.436), and 0.026
(0.213) and 0.106 (0.437) after 56 days.
Although no significant diVerence in time
trend was detected, evaluation of the VA
data of the last time point (56 days) by
means of the Mann–Whitney test showed a
significantly better VA in the vitamin
group (p = 0.01).
Conclusions—There was no significant
eVect of vitamins C and E on laser flare
measurements. The significant eVect of
the oral vitamins on visual acuity at 8
weeks after start of the oral vitamins C
and E may indicate a protective eVect in
patients with acute anterior uveitis.
(Br J Ophthalmol 1999;83:1277–1282)
Free oxygen radicals have an important role in
the initiation and perpetuation of inflamma-
tion associated with experimental uveitis.1–6
These radicals are generated locally by poly-
morphonuclear leucocytes as well as by retinal
cells.7 8 Morphological and biochemical inves-
tigations indicated that free radicals are gener-
ated on sites of uveoretinitis3 4 7 9 and that reti-
nal damage associated with experimental
uveitis is initiated by oxygen radicals causing
peroxidation of retinal cell membrane lipids.3 10
In the anterior segment of eyes with experi-
mental uveitis free radical tissue damage could
be detected.11
In experimental uveitis, several antioxidants
and scavengers of free radicals were shown to
act as anti-inflammatory agents and to protect
the eye from inflammation mediated tissue
damage.1 2 12–16 For instance, vitamin E (á-
tocopherol) diminished inflammation and tis-
sue damage associated with both lens and
S-antigen induced uveitis in rats.17 18 Vitamin C
(ascorbic acid) has radical scavenging, as well
as antioxidant, properties.19 One function of
the normally existing high concentration of
ascorbic acid in the aqueous humour is inhibi-
tion of the activity of polymorphonuclear
leucocytes.20 During experimental uveitis and
alkali burns, vitamin C concentration in the
aqueous diminishes significantly.21 22
The antioxidant and radical scavenging
properties of vitamin E (á-tocopherol) are well
established, although the limited mobility of
á-tocopherol in membranes may interfere with
in vivo activity.23 Vitamin E inhibits both cyclo-
oxygenase and lipo-oxygenase activity and
consequently prostaglandin synthesis.18 In ex-
perimental uveitis, high concentrations of
prostaglandin and inhibition of the active
accumulation of prostaglandins by the anterior
uvea were associated with disease activity.21
From the above it follows that additional
treatment with vitamins E and C may have an
eVect on the duration and intensity of uveitis
and that the deleterious eVects of radicals on
retinal cells may be diminished. There are sev-
eral reasons to administer both compounds
simultaneously. Vitamin E is a lipophilic com-
pound and is mainly active in structures with a
high lipid content such as cell membranes or
serum lipids. Vitamin C is hydrophilic and
therefore is mainly active in compartments like
blood serum, intracellular and extracellular
compartments. By using a combination of the
two compounds, both the lipophilic and
hydrophilic compartments are reached. Addi-
tionally, vitamin C plays a role in regeneration
of oxidised vitamin E.24 Toxic reactions to vita-
min C and to moderate doses of vitamin E are
very rare.25–27
In this study, the potential additional eVect
of oral vitamins C and E on inflammation and
visual acuity changes associated with acute
anterior uveitis treated with local steroids and a
mydriatic were investigated.
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Subjects and methods
All patients presenting with a first or recurrent
episode of anterior uveitis between May 1994
and April 1996 at the first aid department of
the Eye Hospital Rotterdam were asked to par-
ticipate. Exclusion criteria were signs of poste-
rior uveitis, Fuchs’s iridocyclitis, retinitis pig-
mentosa (as prescription of vitamin E might
be deleterious to patients with retinitis
pigmentosa28), severe cataract, corneal graft,
stromal opacities, or corneal oedema in the eye
under study, and patients who already were on
corticoid treatment or any other treatment for
uveitis. To prevent adverse eVects of the
vitamins administered, patients were not al-
lowed to enter the study if they had a history of
a coagulation disorder or regular treatment
with anticoagulants, severe hypertension (di-
astolic pressure > 95 mg Hg despite therapy), a
history of breast cancer, a history of renal
impairment or kidney stones, haemochromato-
sis, polycythaemia, leukaemia, current use of
illegal drugs or excessive alcohol consumption,
pregnancy, lactation or inadequate use of con-
traception during the trial, or who took any
kind of vitamin preparation.
Patient characteristics are presented in
Table 1.
The study was submitted to the ethics com-
mittee of the Eye Hospital Rotterdam and all
subjects gave written acknowledgment of
informed consent to participate before the
start of the study.
Immediately after inclusion, all patients were
treated with one drop of prednisolone acetate
1% six times daily in the aVected eye, one drop
of scopolamine 0.25% three times daily, and 1
cm of prednisolone 0.5% ointment before
sleeping. All local treatment was tapered
according to clinical resolution.
All patients were randomised to treatment
for 30 days with either two capsules daily each
of which contained 500 mg of ascorbic acid
and 100 IU of á-tocopherol (vitamin E) or with
two matching placebo capsules. The vitamin
capsules were manufactured at and distributed
by the hospital pharmacy. A randomisation
table prepared by the statistician was sent
directly to the pharmacy; only the treatment
number was visible during the follow up visits.
Treatment allocations were kept double
masked until the last patient completed the
study.
After inclusion, patients were scheduled to
visit one of the investigators at 3, 7, 14, 28, and
56 days after initiation of therapy. On each
visit, cells and flare were quantified with the aid
of a laser cell flare meter (Kowa FC1000). As
laser flare measurements are an objective,
reproducible, and quantitative variable of ante-
rior segment inflammation,29–36 these were con-
sidered as the primary end point. Clinical vari-
ables such as best corrected visual acuity (VA)
and semiquantitative scores according to the
Hogan-Kimura scale for uveitis37 (that is, pain,
photophobia, hyperaemia, keratic precipitates,
fibrin, synechiae, cells, flare, and ocular pres-
sure) were assessed, as well as the number of
prednisolone and mydriatic drops taken by the
patient.29–36
A venous serum sample was taken from each
patient 1–2 weeks after start of the therapy. In
this serum sample the vitamin E concentration
and HLA-B27 status were determined.
From all patients dietary intakes of vitamin
C and E were assessed by means of an
extensive interview performed by the hospital
dietician.
STATISTICAL ANALYSIS
Flare and cell measurements were analysed
after log transformation and visual acuity (VA)
measurements were transformed to logMAR
equivalents. A repeated measures analysis of
variance (RMANOVA) was used to estimate a
linear time trend of these variables and to test
whether this time trend diVered between the
two treatment groups (vitamins and placebo).
For flare data, additional analyses were per-
formed with vitamin E serum concentrations
as a covariate, and with exclusion of subjects
receiving parabulbar steroid injection(s). The
clinical variables were analysed (also after log
transformation) using a linear random coeY-
cients model with time. A RMANOVA was
used to estimate an average time trend across
all patients and to test whether this time trend
diVered between the two treatment groups.
As the diVerence in VA at the end of the
study was considered of clinical importance
and a time trend was observed in the
RMANOVA, an additional analysis was per-
formed. VA data of the separate measuring
time points were compared using the Mann–
Whitney test. Logistic regression analysis was
Table 1 Patient characteristics
Vitamin C/E Placebo
Average age (min, max) 43.7 (18, 75) 44.7 (21, 70)
Sex (M/F) 35/33 36/31
Concomitant diseases
none 55 51
articular 10 13
autoimmune* 2 2
other 1 1
Race: white/other 57/11 57/10
HLA positive 37 45
Bilateral uveitis 5 0
Former uveitis episodes†:
0 26 25
1 11 12
2 or more 30 30
Contralateral recurrences
0 38 44
1 7 8
2 or more 22 15
*In case of autoimmune articular diseases, this was included as
articular disease.
†Number of recurrences in the treated eye before the episode of
uveitis under study.
Table 2 Average laser cell and flare measurements (SD) for the placebo and vitamin
treated groups
Time (days)
Flare (ph/s) (SD) Cells (no/0.075 mm3) (SD)
Vitamin C/E Placebo Vitamin C/E Placebo
0* 207.1 (258) 143.6 (156) 16.2 (18) 15.9 (19)
3 80.2 (129) 54.7 (82) 5.7 (8) 9.0 (35)
7 89.2 (187) 85.8 (208) 6.0 (10) 5.9 (10)
14 47.1 (109.5) 40.5 (116) 2.7 (6) 2.2 (5)
28 23.1 (53.6) 23.1 (48) 2.2 (5) 1.8 (4)
56 15.6 (26) 15.3 (17) 2.1 (5) 1.9 (5)
p value† 0.53 0.74
*Time 0 days is the measurement before treatment (baseline value).
†Repeated measures analysis of variance.
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used to test the eVect of the two treatments on
VA data; this was followed by the same analysis
of the VA data stratified by HLAB27 status.
Statistical analysis was performed with the
aid of SPSS PC+ version 5 and module 5V of
BMDP (BMDP Statistical Software Inc, Los
Angeles) statistical software.
Results
A total of 145 patients were included in the
study. Five patients were excluded because a
posterior or granulomatous uveitis developed
after randomisation. Five patients were lost to
follow up; four did not adhere to the study pro-
tocol and in one patient cataract flare measure-
ments were not possible.
The average daily dietary intake of vitamin E
was 14.4 (8.6) mg for the vitamin group and
12.2 (6.2) mg for the placebo group. For vita-
min C dietary intake this was 120.6 (76.6) mg
and 124.2 (63.6) mg respectively. Average vita-
min E serum concentrations were 36.8 (13.3)
µmol/l for the vitamin group and 24.0 (13.3)
µmol/l for the placebo group. In seven patients
of the group treated with vitamin capsules the
serum vitamin E concentration was below 23
µmol/l; in these patients compliance was
doubted or absorption was not adequate. As
serum vitamin E concentration was used as a
covariate in statistical analysis, these subjects
were not excluded.
No statistically significant diVerences be-
tween the two treatment groups were found for
any of the semiquantitative clinical variables,
nor for the daily number of prednisolone drops
taken (p>0.1 for all time points; ÷2 test).
Laser flare measurements before treatment
were 207.1 (258) photons per second (ph/s) in
the vitamin group and 143.6 (156) ph/s in the
placebo group (Fig 1, Table 2). After 3 days
corresponding values were 80.2 (129) ph/s and
54.7 (82) ph/s, after 7 days 89.2 (187) ph/s and
85.8 (208) ph/s, after 14 days 47.1 (109.5) ph/s
and 40.5 (116) ph/s, after 28 days 23.1 (53.6)
ph/s and 23.1 (48) ph/s, and after 56 days 15.6
(26) ph/s and 15.3 (17) ph/s. Concerning the
laser flare data, repeated measures analysis of
variance did not reveal a significant diVerence
in time trend between the two treatment
groups (p = 0.53). No significant diVerences
were detected in the additional analyses with
vitamin E serum concentrations as a covariate
(p=0.19), or with exclusion of subjects receiv-
ing parabulbar steroid injection (p=0.63).
Comparison of the flare data of the last meas-
uring point (56 days) by means of the
Mann–Whitney test did not reveal a significant
diVerence (p = 0.9).
The average number of cells/0.075 mm3 as
measured by the laser cell flare meter before
treatment was 16.2 (18) in the vitamin group
and 15.9 (19) in the placebo group (Table 2).
After 3 days corresponding values were 5.7 (8)
and 9.0 (35), after 7 days 6.0 (10) and 5.9
(10), after 14 days 2.7 (6) and 2.2 (5) after 28
days 2.2 (5) and 1.8 (4), after 56 days 2.1 (5)
ph/s and 1.9 (5). There was no significant dif-
ference in time trend between the two treat-
ment groups for the laser cell data (p = 0.74);
the same was the case when the data of the last
measuring point were compared (p = 0.41).
Baseline visual acuity was 0.106 (0.241) log-
MAR in the vitamin group and 0.128 (0.456)
logMAR in the placebo group (Fig 2; Table 3)
Corresponding Snellen visual acuity data are
visualised in Figure 3. LogMAR visual acuity
values were 0.236 (0.293) logMAR and 0.344
(0.489) logMAR after 3 days, 0.204 (0.292)
logMAR and 0.292 (0.479) logMAR after 7
days, 0.162 (0.274) logMAR and 0.193
(0.454) logMAR after 14 days, 0.096 (0.232)
logMAR and 0.158 (0.436) logMAR after 28
days, and 0.026 (0.213) logMAR and 0.106
(0.437) logMAR after 56 days. No significant
diVerence between the two treatments was
detected with RMANOVA; however, evalua-
tion of the VA data of the last time point (56
days) by means of the Mann–Whitney test
showed a significantly better VA in the vitamin
group (p = 0.013; Table 3). Logistic regression
analysis on the influence of the type of
treatment (vitamins or placebo) on VA data
also revealed a significant eVect for the last
time point (p = 0.021 for 56 days). The
vitamin treatment eVect on VA data was not
altered significantly by HLA-B27 status (p
value for the eVect of HLA status on VA data:
0.67 for 28 days and 0.22 for 56 days).
Figure 1 Average laser flare measurements for the vitamin (triangle; n = 68) and placebo
(circle; n = 67) treated patients.
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Figure 2 Average visual acuity in logMAR for the vitamin (triangle; n = 68) and
placebo (circle; n = 67) treated patients. *p Value for Mann-Whitney test on delta VA
(relative to day 0).
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Discussion
In this study no significant diVerence between
oral vitamins C and E and placebo could be
detected regarding the eVect on laser flare and
cell measurements. In spite of higher initial
flare values in the vitamin treatment group and
faster decline during treatment, the compari-
son of the course of flare measurements of the
two treatment groups over time by means of
RMANOVA did not indicate statistical signifi-
cance. The reason for this may be either that
free radical scavengers do not influence the
blood-aqueous barrier in acute anterior uveitis
in humans, or that treating all patients with
potent local steroids possibly prevented the
detection of an eVect of the vitamins on vascu-
lar leakage. In studies using experimental uvei-
tis models, free radical scavengers were dem-
onstrated to have an eVect on uveal and retinal
inflammation.12 13 17 18 In the only animal study
with assessment of eVects on the anterior
chamber reaction,16 in contrast with posterior
segment reactions no eVect on cells or on flare
could be detected.
Although the possibility that a higher vita-
min E dosage exerts more eVect cannot be
excluded, it is improbable that the vitamin
dosages used in this study were insuYcient.
The daily dosage of 200 mg of vitamin E as
used in this study was demonstrated to be
eVective in reducing oxidised serum low
density lipoprotein (LDL) cholesterol.38 After
oral administration to rats, a clear relation
exists between dose and total ocular vitamin E
concentrations.17 18 The fact that in several
studies a preventive eVect of vitamin E on
retinopathy of prematurity could be detected39
indicates that the bioavailability of this vitamin
in the human eye is also proportional (it should
be remembered that high vitamin E dosages in
newborns can be hazardous). In this study the
serum vitamin E concentration was deter-
mined in each patient in order to be able to
adjust for therapy compliance. The average
plasma vitamin E concentration in the subjects
treated with vitamins (36.8 (13.3) µmol/l) is
comparable with plasma concentrations found
in subjects taking 440–1320 mg of vitamin E.40
Concerning vitamin C, in guinea pigs concen-
trations of ascorbate in aqueous humour and
vitreous were proportional to oral doses41 42
with a plateau being reached at higher doses.42
This, in combination with the probability that
most of a daily dosage above 200 mg of vitamin
C will be excreted by the kidneys,24 suggests
that a dosage of vitamin C higher than used in
this study will have no additional eVect.
Although baseline visual acuity in both
treatment groups was similar (Figs 2 and 3),
the curve of the vitamin treated patients
consistently describes a better average visual
acuity on all time points. For the last measure-
ment performed at 2 months after the start of
the treatments, the diVerence in visual acuity
compared with baseline values was statistically
significant (p=0.01). The diVerence between
the average end point VA values expressed in
Snellen equivalents was 0.16; 0.94 for the vita-
min group and 0.78 for the placebo group.
RMANOVA analysis did not show a significant
time-treatment interaction; however, a time
trend was detected, which can also be read
from the curve of the VA data (Figs 2 and 3).
For this reason and the clinical significance of
the diVerence in VA, additional analyses by
means of Mann–Whitney tests were performed
at the separate time points, revealing a
significant diVerence at 2 months after start of
the treatments. This result was confirmed by
the logistic regression analysis of the visual
acuity data. At the last measuring point (56
days), treatments (including mydriatics and
drops containing preservatives possibly aVect-
ing the corneal epithelium) were stopped in
virtually all patients, omitting eVects of these
on visual acuity. Additionally, in virtually all
patients disease activity can be expected to
have subsided 2 months after the start of the
treatments, permitting correct comparisons of
VA data at this time point. As the average
course of HLAB27 positive anterior uveitis
treated in a similar way as in this study does not
extend beyond 10–14 days for most patients,34
results of a longer follow up are not expected to
be very diVerent. We examined the eVect of
HLAB27 (+ or −) status on the vitamin treat-
ment eVects exerted on visual acuity data.
Logistic regression resulted in a p value of
0.22, indicating that there was no eVect of
HLAB27 status on VA data. This means that in
our patients HLAB27(+) or HLAB27(−)
status did not aVect the protective eVect of free
radical scavengers on photoreceptors.
The better preservation of visual acuity in
the patients treated with vitamins is possibly
Figure 3 Average visual acuity in Snellen equivalents for the vitamin (triangle; n = 68)
and placebo (circle; n = 67) treated patients.
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Table 3 Average visual acuity (logMAR (SD)) for the
placebo and vitamin treated groups
Time (days)
Visual acuity in logMAR* (SD)
p Value†Vitamin C/E Placebo
0‡ 0.106 (0.241) 0.128 (0.456)
3 0.236 (0.293) 0.344 (0.489) 0.13
7 0.204 (0.292) 0.292 (0.479) 0.10
14 0.162 (0.274) 0.193 (0.454) 0.66
28 0.096 (0.232) 0.158 (0.436) 0.09
56 0.026 (0.213) 0.106 (0.437) 0.013
*logMAR is the negative 10th power logarithm of Snellen visual
acuity. †p Values for delta VA (relative to day 0) in logMAR;
Mann–Whitney test. ‡Time 0 days is the measurement before
treatment (baseline value).
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achieved by the free radical and antioxidant
properties of one or both of the vitamins used.
The existence of free radicals in the posterior
segment of animals with experimental uveitis
was studied with the aid of histochemical
methods4 7 and chemiluminescence9 and free
radical tissue damage could be detected in the
anterior segment of eyes with experimental
uveitis.11 In experimental uveoretinitis lipids of
the membranes of retinal cells are oxidised by
the free radicals.5 43 The membranes of the rod
outer segments are particularly vulnerable to
peroxidation as in this segment more than 65%
of the membrane fatty acids are
polyunsaturated.39 Peroxidation of cell mem-
brane lipids can lead to necrosis of photorecep-
tors and other retinal cells.3 9 Several antioxi-
dants and scavengers of free radicals, including
vitamin E, were shown to protect the eye from
inflammation mediated tissue damage.1 2 12–18
The data of the aforementioned experimental
studies may indicate that, in the patients in this
study who were treated with vitamins C and E,
the photoreceptors were protected from free
radical damage leading to a better preservation
of VA. The fact that in experimental uveitis
vitamin C concentration in the aqueous dimin-
ishes significantly21 22 suggests that oxygen
radicals are indeed scavenged during uveitis
and that there may be an insuYcient buVer of
vitamin C during moderate to severe uveitis.
Apart from the possible protective eVect of the
vitamins on photoreceptors, other mechanisms
may explain the diVerence in VA. Cystoid
macular oedema (CMO) is a well recognised
mechanism of transient or definite loss of VA in
uveitis patients, and this may not be detected
on indirect funduscopy (as was performed on
each follow up occasion). Although the patho-
physiology of CMO is not well understood,
prostaglandins may have a role, and vitamin E
was reported to influence prostaglandin
metabolism.18 As free oxygen radicals are
generated early in the inflammatory cascade, a
protective eVect on CMO of free radical
scavengers cannot be excluded. There was no
significant eVect of HLAB27 status on end
point visual acuity, suggesting that a possible
protective eVect of free radical scavengers
applies to both HLAB27 positive and negative
patients.
We conclude that in this study no eVect of
oral vitamins C and E on flare or cell measure-
ments could be detected in patients with acute
anterior uveitis, possibly because all patients
were treated with potent local steroids.
Visual acuity at 2 months after start of the
treatment was significantly better for the pa-
tients treated with vitamins C and E, although
this was not confirmed by RMANOVAs. This
suggests a protective eVect of free radical
scavengers on photoreceptors in uveitis patients;
possible mechanisms include prevention of pho-
toreceptor damage or cystoid macular oedema.
The authors are grateful to Mr JTG Jansen, hospital pharmacist
of the Eye Hospital Rotterdam, for the preparation and double
masked distribution of the vitamins C and E capsules and Miss
J van Hal, dietician of the Eye Hospital Rotterdam, for the
interviews to calculate dietary intakes of vitamins C and E.
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